The background (no peptides) IFNγ responses, summed from all three sets of the glioma patient’s PBMC, measured 0.78% ± 1.05% for CD4+ T cells and 0.016% ± 0.02% for CD8+ T cells. This evidence concerns the gene CD8A and glioma.